Press release

18 May 2022 London, GB

EY announces EY Life Sciences Industry Cloud for SAP® solutions to help the cell and gene industry improve therapy data access

LONDON, 18 MAY 2022. The EY organization today announces a new offering the EY Life Sciences Industry Cloud for SAP solutions to help the cell and gene therapy (CGT) industry improve efficiency and increase the speed to market of CGT.

Press contact
Jennifer Noel

Assistant Director, Media Relations and Social Media, Ernst & Young LLP

Leader in the business of brand building and corporate positioning. Lover of written and spoken word. Proud New Yorker.

  • Creates seamless interaction among stakeholders in the cell and gene therapy (CGT) ecosystem by providing a single source of data
  • Helps scale up manufacturing of CGTs by improving efficiency and speed to market
  • Provides earlier access to alerts and issues at any point of the treatment journey

The EY organization today announces a new offering the EY Life Sciences Industry Cloud for SAP solutions to help the cell and gene therapy (CGT) industry improve efficiency and increase the speed to market of CGT. The offering leverages SAP cloud technology to help deliver a leading-class solution that easily integrates across the wide-ranging infrastructure of EY clients and the industry.

Pamela Spence, EY Global Health Sciences and Wellness Leader says:

“CGTs are ushering in a transformative era in medicine, with the number of patient treatments expected to grow from hundreds today to hundreds of thousands by the end of the decade. But these rapidly growing therapies are complex and expensive to manufacture and administer. How can data related to CGTs be made more easily accessible? Today the CGT industry lacks the shared data standards, interoperable systems and streamlined processes to reliably communicate and coordinate across a patient’s treatment journey. To help make CGT available at scale for those in need, EY teams have created EY Life Sciences Industry Cloud for SAP solutions to address these challenges for those on existing SAP platforms.”

Mandar Paralkar, Global Vice President, Life Sciences, SAP, says: “EY Life sciences Industry cloud applications running on SAP cloud technology complement the intelligent suite capabilities delivered by SAP to drive tangible business outcomes.”

EY Life Sciences Industry Cloud for SAP solutions is comprised of Pointellis™, an information exchange and web application that will serve as a digital backbone to help link all the key stakeholders in the CGT ecosystem. Realizing scale and availability of CGTs requires a strong information foundation. Pointellis™ running on SAP cloud technology can fill the information gap, acting as an information exchange, connecting data and network nodes outside of SAP.

Pointellis™ provides:

  • Flexible, cloud-based architecture that easily evolves and expands to meet rapid growth and diversity within commercialization.
  • A suite of applications aimed at solving specific challenges within the industry by turning data connections into actionable information.
  • Compliance enablement with cybersecurity, data privacy, Health Insurance Portability and Accountability Act (HIPAA) and other regulatory requirements.

The Pointellis™ suite of applications provides users with actionable information they need to address the complex challenges of accessing data on CGTs. The cloud-based applications are accessible through SAP Fiori ® apps and integrated with EY Intelligent Life Sciences SAP S/4HANA® system.

  • Pointellis™ Case Assist will help enable health care providers, drug manufacturers and transporters to share information about status changes, notifications, and pending requests. Case Assist will provide a holistic view of the treatment journey for the patient from collection, to manufacturing, to delivery back to the patient, with options to search, export and audit all associated data.
  • Pointellis™ Slot Schedule will give manufacturing teams and health care providers the ability to anticipate treatment progress, view the manufacturing capacity and status, and provide centralized scheduling, sequencing, and rescheduling of CTGs. Optimizing the limited number of “slots” available to manufacture therapies in order to achieve fast and cost-effective production relies on several variables that are dependent on each other.

For more information, visit             


About EY

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit

This news release has been issued by EYGM Limited, a member of the global EY organization that also does not provide any services to clients.